MDACC Study No:2010-0492 ( NCT No: NCT01263899)
Title:A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Principal Investigator:Michelle A. Fanale
Treatment Agent:SB1518
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if SB1518 can help to
control lymphoid cancer. The safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:SB1518
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:S*Bio Pte Ltd
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults